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A B S T R A C T
Supercritical fluid (SCF) technology has been applied to drug product development over the last thirty years and
drug particle generation using SCFs appears to be an efficient way to carry out drug formulation which will form
end-products meeting targeted specifications. This article presents an overview of drug particle design using
SCFs from a rather different perspective than usual, more focused on chemical and process engineering aspects.
The main types of existing processes are described in a concise way and a focus is put on how to choose the right
operating conditions considering both thermodynamic and hydrodynamic aspects. It is shown that the operating
conditions and parameters can be easily optimized so as to facilitate the further process scale-up. Furthermore,
the new trends in particle generation using SCFs are introduced, related either to new types of drug medicines
that are treated or new ways of process implementation methods.
1. Introduction
The main aim of drug formulation is to fulfil end-product specifi-
cations with regard to drug bioavailability, non-toxicity, uniformity,
stability and handling properties. It is possible to enhance drug bioa-
vailability, while meeting given specifications, either by micronizing
the pure Active Pharmaceutical Ingredient (API), by modifying the
crystal characteristics (habit and/or polymorphic nature), or by
forming composite particles. Composite particles used as controlled or
sustained release drug delivery systems can be matrix carriers, such as
polymer-based or silica-based particles, or soft matter vesicular carrier
as liposomes. The release of the drug can be accelerated or slowed down
according to the nature of the excipient, thus allowing an optimization
of the quantity of administrated drug, an increase in the benefit/risk
ratio of the drug and better patient compliance.
Supercritical fluid (SCF) technology has been applied to drug for-
mulation for the past 30 years and is now acknowledged as being a real
alternative to conventional techniques using liquid organic solvents.
Depending on the system under study, it is possible to either completely
avoid the use of organic solvents, or, when their use is unavoidable,
significantly reduce their quantity compared to many industrial pro-
cesses. For these reasons, among others, it is generally accepted that
processes using SCFs are environmentally friendly. In addition, the re-
sulting end-products contain few to no traces of residual organic sol-
vent.
More than a hundred APIs and a large number of excipients have
been processed, using supercritical carbon dioxide (SC CO2) for the vast 
majority of cases [1–5]. One of the most interesting properties of CO2
for such applications is its low critical temperature (Tc = 304.21 K) and 
its easily-accessible critical pressure (Pc = 7.38 MPa). This is a real 
advantage as a large number of pharmaceuticals are thermosensitive.
Another benefit of using SC CO2 is that carbon dioxide is gaseous 
under ambient conditions of pressure and temperature, thus enabling 
the end-product to be separated spontaneously from CO2 simply by 
depressurizing. This means that SC CO2 processes require a reduced 
number of unit operations compared to conventional methods which 
need several successive steps of drying and separating in order to re-
cover a solvent-free end-product. Needless to say, a process requiring a 
reduced number of steps has the added advantage of forming products 
with homogeneous characteristics as there are fewer stages at which the 
properties of the product may evolve. For instance, in a multi-step 
crystallization process, the resulting crystals may evolve during the 
successive steps, thus exhibiting different characteristics in terms of size, 
particle size distribution, habit or polymorphic nature.
Furthermore, one is more likely to accurately control product 
characteristics using SCFs because of the large number of operating 
parameters and conditions (pressure, temperature, nature of the phases 
in presence, compositions, flow rates, introduction modes, mixing 
conditions,…) which can be varied in order to obtain an end-product 
with specific properties. Polymorphic screening, for example, may be 
more successful with SCFs than with conventional methods.
At the same time, over the past 20 years, an alternative to
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2. Current state of particle generation processes
These processes are applied either to the pure drug with the ob-
jective of micronization or modification of crystal morphology, habit or
polymorphic form or to the drug in presence of one or more excipients
for the purpose of slowing down or enhancing the drug release, of
protecting/stabilizing the drug during storage or in the human body
after its administration, of masking a bad taste, etc.
Processes of particle generation are almost always classified ac-
cording to the role played by the supercritical fluid, acting as a solvent
of precipitation, as an anti-solvent or as a dispersing agent. For greater
clarity, this classification will be followed here and in addition, the
different processes will be detailed from a chemical engineering angle.
In particular, for each type of process, it will be discussed how better to
control the end-product characteristics by choosing the right operating
conditions. This is possible by considering both thermodynamic and
hydrodynamic aspects. In recent years, many works have demonstrated
that either experimental or modeling tools allow a deeper compre-
hension and mastering of the processes. We will detail here the main
items to be considered for the three process types.
2.1. SCF used as precipitation solvent
When the SCF is used as a solvent, the process implies a first step of
drug solubilization in the SC phase followed by an expansion of the
resulting solution in a lower pressure vessel. The dramatic decrease in
the solvent power during depressurization leads to high solute super-
saturations and the formation of ultrafine particles. The most com-
monly used process using SCF as solvent is the Rapid Expansion of a
Supercritical Solution (RESS) process.
This process is suitable for solutes having a solubility higher than
about 10−3 g g−1 of SCF. The drug solubilization is carried out in a
high-pressure cell (often called extraction or saturation vessel) swept by
a continuous SCF flow rate. Depending on this flow rate and on the
system studied, the concentration of the solute in the SCF reaches the
solubility value. If the SCF-rich phase is saturated, the resulting su-
persaturation achieved during depressurization will be higher, the
overall SCF consumption lower and the process productivity enhanced.
The conditions of pressure and temperature (in the saturation and in the
expansion vessels), the SCF flow rate as well as the geometry and dia-
meter of the expansion nozzle/tube thus have to be carefully chosen.
Regarding the precipitation phenomenon during the RESS process,
it occurs in a transitory regime. Pressure, temperature, composition/
supersaturation vary during the expansion of the SC solution; the latter
occuring through capillary tubes or nozzles (with an internal diameter
of a few tens of microns) at supersonic jet velocities according to the
different cases, leading to high nucleation frequency. Crystallization
characteristic times are commonly lower than 10−5 s. A thorough un-
derstanding of the different mechanims involved in this rapid pre-
cipitation/crystallization is thus difficult.
Nevertheless, a large number of molecules have been micronized
using the RESS process, most of them are small molecules, as for ex-
ample acetylsalicylic acid, artemisinin, aspirin, β-carotene, β-estradiol,
β-sisosterol, caffeine, carbamazepine, cyclosporine, fenofibrate, fla-
vone, griseofulvin, ibuprofen, lazaroid, lidocaine, loperamide, me-
droxyprogesterone acetate, salicylic acid, taxol or testerone. A number
of polymeric excipients have also been treated by RESS. We can enu-
merate the following:
– polyhydroxic acids (polylactic acids–L-PLA and D,L-PLA, polyglycolic
acid–PGA),
– polyacrylates polymethyl of methacrylate – PMMA, PMMA-co-poly
(glycidyl methacrylate), Poly(2-ethylhexyl acrylate), Poly(heptade-
cafluorodecyl acrylate),
– polyenes and polyvinyls Polyethylen Glycol – PEG, Polypropylen,
PEG- polypropylen glycol, poloxamers, ethylen–buten copolymers,
Polystyren, Ether de Poly(oxyalkylene) alkylphenyl ether,
Polyvinylpyrrolidone − PVP, fluorure of Polyvinyliden, Poly(vinyl
chlorure-co-vinyl acetate),
– cellulosic derivates (hydroxypropyl of cellulose, ethyl cellulose,
triacetate of cellulose),
– other polymers (Hyaluronan-based polymer as HYAFF-11, Poly(di-
methylsiloxane), bisphenol epoxy resin, perfluoro polyether).
When carbon dioxide is used as SCF, since it is apolar, the RESS
process is more adapted to non-polar molecules eventhough the ex-
amples cited above show that polar molecules can also be re-
precipitated by RESS process.
2.1.1. Choice of operating conditions
Pressure and temperature conditions in the saturation vessel are key
conventional medicinal therapy using anti-inflammatory drugs, gluco-
corticoids or immunosuppressants which can cause immediate or de-
layed adverse effects, has emerged. The strategy of this alternative 
therapy, which is also used for the treatment of genetic diseases, con-
sists in using small molecules of RiboNucleicAcids (RNAs) to modulate 
endogenous gene expression. These small RNAs could constitute an 
innovative therapeutic solution for a large number of diseases. However, 
it is necessary to elaborate RNA formulations adapted to this molecule, 
the downside being that a non-protected strand of RNA will degrade 
rapidly in vivo under the action of endogenous ribonucleases or due to 
pH variations. Moreover, it is possible that a treatment using interferent 
RNAs could induce immune responses or cause adverse ef-fects. In order 
to circumvent these problems, it is possible to en-capsulate or trap the 
RNA molecule thus ensuring its protection once absorbed and linking it 
to the vector agent transporting it to the target organ. For about fifteen 
years, different types of RNA formulations have been elaborated using 
conventional methods [6] but also using SCFs [7–9] and their efficiency 
has been studied in vitro and in vivo.
There are two main SCF processes for elaborating controlled or 
sustained release drug delivery systems: i) particle generation pro-
cesses, which use the SCF as a solvent, an anti-solvent or a dispersing 
agent; ii) impregnation processes for which the SCF is the impregnation 
agent/solvent. As in some particle generation processes, there is a so-
lubilization step of the drug in the SC phase during the impregnation 
process. Hence, this drug solubilization can only be achieved for certain 
conditions of chemical affinity with the SC phase and of molecular size. 
Supercritical drug impregnation has been successfully applied over the 
last years to different types of supports, mainly “non-swellable” mate-
rials like silicas or “swellable” matrices like polymers. This technic is 
suitable for a drug amorphization [10]. The current new trend for SC 
impregnation is to impregnate medical devices [11] since it is possible to 
perform a homogeneous drug impregnation without modifying the 
properties of the impregnated support [12]. Supercritical drug im-
pregnation will not be addressed in this paper which is dedicated to 
particle generation processes.
This article aims to lay out the current situation for the various 
processes of drug particle generation using SCFs hence guiding the 
reader in his or her choice to find the right process according to both the 
nature of the drug solute and the end-product or application de-sired. 
The different processes for the elaboration of controlled or sus-tained 
release drug delivery systems will be described in a concise and 
comparative way. The main issues linked to industrial scale-up will also 
be highlighted, taking into account that this scale-up will be easier once 
the different process steps are better controlled. This will be achievable 
after obtaining more thermodynamic data and knowledge about the 
transfer phenomena involved in the different processes. These aspects 
need to be addressed so as to fill the gaps in the knowledge about these 
technologies.
Lastly, novel views, mainly directed towards process intensification 
and process coupling will be outlined.
concern. It implies collecting particles that are expected to be easily 
handled, without fine dust emissions and with a good flowability. One 
solution can be to trap the active principle solute in a fixed bed of ex-
cipient placed in the collection chamber. This approach was applied to 
the production of a powder constituted of sirolimus nanoparticles de-
posited on particles of microcrystalline cellulose [17]. Lastly, the en-
thalpy input during the fluid depressurization step is a major en-
gineering difficulty. An intensive heating of the depressurization line is 
needed to avoid the CO2 condensation and an early solute precipitation. 
This is rather easy to implement at lab-scale but more difficult at larger 
scale. Innovative solutions have to be proposed for overcoming these 
issues.
2.2. SCF used as precipitation anti-solvent
When the SCF is used as an anti-solvent, the principle is the same as 
for conventional methods of recrystallization using a liquid anti-sol-
vent. In that case, the solute to be precipitated is first solubilized in a 
liquid organic solution which is subsequently put into contact with the 
SCF. The organic solvent is chosen so as to be miscible in all proportions 
with the SCF. There are different processes using SCF as anti-solvent, 
they mainly differ from each other by the mode of introduction or the 
way of putting the two phases into contact. Among these different 
processes, the Supercritical Anti-Solvent (SAS) process is the most 
widely used.
When SC carbon dioxide is used, the SAS process is well adapted to 
most drug molecules which are often polar and may thus exhibit low 
solubility in SC CO2. Over the last thirty years, dozens of drug solutes 
have been recrystallized pure or co-precipitated with excipients using 
SC anti-solvent techniques. As for examples, several works on acet-
aminophen, albumin, amoxicillin, ascorbic acid, aspirin, carbamaze-
pine, cefuroxime, cholesterol, dexamethasone acetate, indomethacin, 
insulin and naproxen have been reported with or without excipients. All 
the polymeric excipients cited in the previous section have been used 
for SAS formulations.
A single vessel is used for the SAS process (Fig. 3), swept by a 
constant and continuous SCF flow rate. The solution containing the 
solubilized solutes (active pharmaceutical ingredients and excipients) is 
introduced in the high-pressure vessel through a capillary tube or nozzle 
(internal diameter varying from about 60–500 μm). The si-multaneous 
diffusion of the SCF in the liquid solution and of the organic solvent 
towards the continuous SC phase lead to the solute super-saturation and 
its crystallization/precipitation. The solid particles formed accumulate 
in the high-pressure cell and are collected after the depressurization. A 
well-known derivative of the SAS process is the Supercritical Enhanced 
Dispersion Solution (SEDS) process which uses a multichannel nozzle 
with a pre-mixing chamber for the introduction of the phases [1]. As 
represented in Fig. 3, the two phases can also be fed into the autoclave 
using impinging jets [18]. For both latter modes of introduction, mixing 
conditions are enhanced.
Fig. 1. Solubility of Pyridin-4-amine in SC CO2 as a function of pressure and for different 
temperatures [13].
parameters that are chosen regarding the solute solubility in the SCF. It 
is recommended thus to evaluate its value as a function of pressure and 
temperature. As for example, the solubility of pyridin-4-amine was 
measured by Chen et al. [13] prior to RESS experiments. The values of 
the solubilities as a function of pressure and for different temperatures is 
reported in Fig. 1. These measurements enable the identification of the 
retrograde zone (below 12 MPa) where the solubility decreases when the 
temperature increases.
Fig. 1 Since a solute’s solubility increases when pressure increases, 
the RESS process is often operated at pressure higher than 10 MPa. The 
operating conditions of pressure and temperature usually ranges be-
tween 10 and 40 MPa and between 308 and 333 K. A liquid co-solvent 
(generally from 1 to 5 wt%) is sometimes used for increasing the solute 
solubility in the SC phase. In that case, the conditions of particle col-
lection have to be well controlled in order to avoid the condensation of 
the co-solvent during depressurization. A solid co-solvent can also be 
used [14]; in that case the recovery of a dry end-product is easier.
Different works reported in literature over the last fifteen years have 
demonstrated that RESS-type processes can be very efficient for the 
coating of active pharmaceutical ingredients. Sub-micronic particles of 
flavone have been successfully coated by PEG at 308 K and 20 MPa (Fig. 
2a) [15]. It is worth noting that the RESS process can be ad-vantageously 
coupled with a fluidization bed allowing the coating of API particles. 
Schreiber et al. [16] obtained a homogeneous coating film of paraffin on 
the surface of lactose beads (Fig. 2b).
To conclude on RESS-type processes, it should be noted that the ratio 
SCF/solute is quite high (from 10 to 1000 kg kg−1 of solute) but this 
might not be an issue with the implementation of an efficient loop of SCF 
purification and recycling at larger scale. Besides the SCF management, 
the collection of the generated particles is a major
Fig. 2. (a) Flavone particles trapped in a polymeric
matrix by a RESS-type process [15]. (b) Lactose
beads coated by paraffin using RESS coupled with a
fluidized bed [16].
This process is of great interest since the crystallization occurs in
steady state conditions: constant pressure, temperature, global fluid
composition, flow rates…. As a consequence, the resulting particles
may theoretically exhibit more homogeneous and repeatable char-
acteristics than the ones obtained by processes involving a transient 
state crystallization. Moreover, such conditions of permanent regime are 
suitable for conducting fundamental studies (experimental or modeling 
ones) on the crystallization mechanisms, kinetic transfers and so on. The 
SAS process thus appears to be the most interesting process allowing a 
good control of the end-product characteristics. A drawback remains the 
use of an organic solvent but it has to be underlined that not only a non-
toxic solvent as ethanol can be used but also edible or harmless 
compounds can play the role of solvent in the SAS process. For instance, 
the SAS process is used at an industrial scale for the produc-tion of 
micronized lecithin powder without the use of any organic solvent [19]. 
The mother solution is composed of phospholipids solu-bilized in a 
lipidic oil solution. The oil is soluble into SC CO2 and this latter plays the 
role of anti-solvent for phospholipids which precipitate. Dry particles of 
lecithin can then be produced by SAS process at a production rate of 200 
kg h−1 without using any organic solvent.
Lastly, and still with regard to the use of organic solvents, some 
difficulties may occur at industrial scale to achieve a complete removal 
of residual solvent traces when low-volatile solvents are used, such as 
dimethyl sulfoxide or N-methyl pyrrolidone. It is thus recommended to 
use preferentially volatile solvents.
2.2.1. Choice of operating parameters considering both thermodynamic and 
hydrodynamic aspects
2.2.1.1. Choice of P, T and global composition. Depending on the operating 
conditions in terms of pressure, temperature and composition, the 
nature of the phases in presence in the precipitation vessel will be 
different, leading to different conditions of mass transfer and phase flow. 
In a first attempt, the operating pressure and temperature can be chosen 
referring to the CO2–organic solvent binary diagram, P-x. They are 
usually chosen so that the operating point is outside the biphasic 
envelope and for pressure and composition corresponding to a 
supercritical fluid phase, that is to say above the Mixture Critical Point 
(MCP). The MCP moves towards higher pressures and lower CO2 molar 
fraction when the temperature increases as it is illustrated in Fig. 4 for 
the binary system CO2-Methanol [20]. Since the presence of the solute 
has an impact on the phase behavior, the knowledge of the fluid phase 
equilibria of the ternary systems (CO2-organic solvent-solute) may be 
helpful. Several hundreds of high pressure fluid phase equilibria for 
binary and ternary systems have been reported recently in the literature 
[21] and they are highly useful
Fig. 3. SAS process flow diagram.
Fig. 4. P-x phase diagram of the CO2 + methanol at different temperatures. Solid lines 
correspond to SAFT-VR predictions using Lorentz–Berthelot combining rules, while 
symbols correspond to experimental data: ○, 273.15 K; □, 290.00 K; ◊, 298.15 K; ▵, 
310.00 K; •, 313.14 K; ×, 323.20 K; +, 330.00 K; ▿, 352.60 K [20].
for determining the right SAS process operating conditions.
2.2.1.2. Choice of flow rates. Once the pressure, temperature and global 
composition set, the flow rates of both the SCF and the organic solution 
have to be fixed. A given global composition can indeed correspond to 
different flow rates. The conditions of dispersion of the organic solution 
in the continuous supercritical one as well as the mixing conditions in 
the precipitation vessel have been studied by several authors [18,22–
26]. For similar conditions of P, T and global composition, it has been 
proved that the characteristics of the obtained powder are significantly 
influenced by the flow and mixing conditions.
As stated above, crystallization by the SAS process presents the 
advantage of occuring in a steady state regime, unlike RESS and PGSS-
type processes. In order to ensure these steady state conditons regarding 
the organic solvent/CO2 ratio of the continuous fluid phase in the au-
toclave, it is necessary to introduce pure organic solvent prior to the 
introduction of the solution containing the solute to be precipitated. 
Indeed, to achieve a constant organic solvent/CO2 ratio corresponding 
to the flow rate ratio of both phases, it is necessary to feed the autoclave
zone.
2.2.2. Crystallization phase
The duration of the crystallization phase is of great importance since 
the powder characteristics can evolve during this stage in the autoclave. 
The continuous phase (rich in CO2) contains organic solvent and the 
solubilized solute. Even for solutes presenting rather low solubilities in 
the SC phase, crystal evolution can be observed if the crystallization 
phase is long. Crystal growth can occur/continue and some variations in 
size, habit or even polymorphic transition may happen. Some authors 
have performed the recrystallization of sulfathiazole using the SAS 
process and have varied, among other parameters, the duration of the 
crystallization step from 3 to 8 h [27]. They have obtained different 
polymorphic forms depending on the duration. For instance, they ob-
tained a pure polymorphic form (form IV) with a duration of 4 h while a 
mixture of two different polymorphic forms (forms IV and I) was ob-
tained after 8 h of crystallization in similar conditions [27]. It is ad-
visable to pay attention to the duration of the precipitation phase during 
the scale-up so as to avoid the formation of an unexpected form.
2.2.3. Washing step
Once the precipitation phase is finished, a washing step is required in 
order to avoid organic solvent condensation during depressurization and 
the presence of residual traces of organic solvent in the powder. This 
washing step is then conducted for renewing the fluid phase in the 
autoclave and consists in sweeping this latter with a pure CO2 flow. In 
order to optimize this phase, it is recommended to introduce the CO2 by 
the top of the autoclave. Indeed, since the pure CO2 is lighter than the 
binary fluid mixture CO2-organic solvent, the autoclave behaves like a 
plug flow reactor if CO2 is introduced by the top while it behaves like a 
well-mixed reactor if CO2 is introduced by the bottom. This has been 
established by RTD measurements conducted under classical SAS con-
ditions. As illustrated in Fig. 7, a plug flow reactor behavior is preferred 
since it corresponds to lower required washing times to renew the 
content of the autoclave.
Once the washing step is finished, the precipitation vessel can be 
depressurized and the particles collected. This collection is easier for the 
SAS process than for RESS-type or PGSS-type processes since the 
particles have been accumulated in the high-pressure vessel and their 
recovery consists in emptying it. Nevertheless, since the particles are 
often fine ones, their collection requires adapted solutions. The dif-
ferent considerations are discussed in the section Challenges.
To illustrate the influence of operating process parameters upon the 
particle characteristics discussed above, we can cite the example of 
cefuroxime precipitated from DMSO solutions [28]. Varying the initial 
solute concentration, the authors observed different morphologies (see 
Fig. 8) and link it to the location of the process operating point in re-
lation with the ternary system mixture critical point. The « wrinkled 
particles » were obtained for more concentrated solute solutions; these 
conditions may correspond to a precipitation in a subcritical gaseous 
phase.
In recent years, the SAS process has been proven to be highly effi-
cient either for the micronization of pure drug or for encapsulation. It is 
worth mentioning here that cocrystals have also recently been formed 
by anti-solvent technics [29].
As for an example for successful encapsulation, stable formulations 
of quercetin have been elaborated using the SAS process [30]. Quer-
cetin is an antioxidant exploited for pharmaceutical and cosmetic ap-
plications, thus presenting a high risk of oxidation and poor water so-
lubility. Quercetin (Fig. 9a) was firstly micronized pure using ethyl 
acetate as a solvent at 10 MPa and 308 K. Submicronic crystals were 
obtained (Fig. 9b). In similar conditions and in presence of ethyl cel-
lulose as excipient, solid dispersions of amorphous quercetin in ethyl 
cellulose were formed exhibiting an encapsulation efficiency up to 99%
and with a process yield above 85% (Fig. 9c). The stability of copre-
cipitates were tested after one-year of storage; no reduction in
Fig. 5. Comparison between a well-mixed reactor model and an experimental RTD for a 
1.5 L vessel at 8.6 MPa, 313 K, CO2 flow rate of 622 g h−1, liquid flow rate of 0.25 mL min
−1 [22].
with pure solvent during a given duration. This duration can be esti-
mated taking into consideration the macromixing in the autoclave. 
Carretier et al. [22,23] have characterized macromixing in the SAS 
precipitation vessel by determining the residence time distribution 
(RTD) using a tracing method. Step injections of toluene, used as a tracer 
in ethanol, were done simulating the organic solution injection during 
the precipitation step. The liquid injection was stopped and the 
evolution of solvent concentration into the precipitation vessel was 
recorded. In the experimental domain of operating conditions com-
monly used in the SAS process, the authors varied the flow rates of both 
liquid and SC CO2 phases, the CO2 density as well as the geometry and 
volume of the autoclave. It has been shown that the precipitation vessel 
behaves like a well-mixed flow reactor whatever the conditions used as 
illustrated in Fig. 5 where the concentration C on the y-axis corresponds 
to the tracer concentration in the outlet stream of the autoclave, mea-
sured using an online UV detector. The precipitation vessel is self-mixed 
by the injection of the two phases. The time required for achieving the 
targeted constant organic solvent/CO2 ratio can then be estimated 
considering a well mixed flow reactor behavior. Once the steady state is 
achieved, the feed in the pure organic solvent is stopped and replaced by 
a feed with the organic solution containing the solute to be pre-cipitated.
In most cases, a capillary tube is used for the dispersion of the or-
ganic solution in the crystallization vessel. The organic solution flow 
rates usually used correspond to laminar flows which, depending on the 
operating conditions, lead to liquid jet atomization. Several authors 
have studied jet hydrodynamics in the SAS process and its influence on 
product characteristics. This is of great interest since it has been proved 
that for similar operating conditions in terms of P, T and global com-
position, different hydrodynamic conditions lead to different properties 
of the end-product in terms of size, particle size distribution, poly-
morphic nature and so on. As recalled above, the macromixing was 
characterized for usual SAS conditions and the precipitation autoclave 
behaves like a well-mixed reactor during the introduction phase of the 
organic solution. It is then neceassry to go further in the hydrodynamics 
effects at a microscale as the micromixing and the jet dispersion modes 
can significantly influence the transfer phenomena during the crystal-
lization.
The liquid laminar jet of the organic solution is then dispersed in the 
SC continuum through different dispersion modes depending on jet 
velocities: axisymmetrical, asymmetrical or atomized jet. Petit-Gas et al. 
[25] have shown that the critical atomization velocity is 0.38 m s−1 for 
different solvents and for usual SAS operating condi-tions. It thus 
appears that for the large majority of cases, the velocities used in the SAS 
process lead to jet atomization. If more efficient mixing conditions are 
expected, the jet velocity of the organic solution should be higher that 
this atomization threshold. The same authors visualized the jet 
dispersion in presence of the solute during the precipitation phase (Fig. 
6). It is worth noting that for their studied sytem and op-erating 
conditons, the precipitation was initiated in the jet dispersion
different authors that a particular attention has to be paid to the pH 
conditions.
In sum, it has been underlined that SAS-type processes enable a large 
number of active pharmaceutical ingredients to be treated. However, it 
should be pointed out that a significant number of APIs, especially 
biomolecules, are water soluble and in that case, SAS process operating 
conditions have to be adapted since water has a limited so-lubility in SC 
CO2. For such molecules, a first solution is to use a mix-ture of ethanol 
and water to solubilize the drug and choose the right operating 
conditions for complete water removal during the precipita-tion phase. 
Another alternative is to start from an aqueous solution of the active 
ingredient but to use a mixture of carbon dioxide and of organic solvents 
as supercritical fluids. Bovine serum albumin, initially solubilized in 
water has been micronized using carbon dioxide in mixture with 
ethanol, acetone or isopropyl alcohol [35]. Proteins have also been 
successfully precipitated from emulsions [36]. Microspheres of PLGA 
loaded with insulin have been elaborated by Supercritical Emulsion 
Extraction in a continuous mode and the drug release has been studied 
in myoblast culture [37].
It is also worth noting here that others compounds than CO2 can be 
used. As for an example, dimethyl ether (DME) is already accepted by 
several drug agencies as a “generally recognized as safe” (GRAS) sol-
vent and appears to be efficient for drying biomolecules. DME is thus an 
interesting alternative to CO2 even if precautions must be taken to 
prevent explosion hazards.
Finally, the Supercritical Assisted Atomization (SAA) process 
broadens the scope of the SC anti-solvent techniques of particle gen-
eration, in particular, by allowing the treatment of aqueous phases. In 
this process, the solution containing the solute to be precipitated is 
saturated with CO2 in a packed mixing cell. This saturated solution is 
dispersed using an injection nozzle into a second cell in which the 
precipitation takes place. The atomization of the solution is assisted by a 
nitrogen flow at a higher temperature. The size of the formed particles 
varies from several dozens of nanometers to several hundreds of mi-
crons depending on the system studied and operating conditions.
Fig. 6. Jet dispersion and crystallization of SFZ from DMF solutions (10 wt%) with a 510 μm capillary under 11MPa, 308 K and for a composition of 8mol% of solvent in the continuous
phase [24].
Fig. 7. Experimental RTD respectively related to the introduction of the antisolvent through 
the top or through the bottom of a 0.75 L vessel at 8.6 MPa, 313 K, CO2 flow rate of 622 g h
−1 [22].
antioxidant activity was observed.
Another example of successful encapsulation but with lower drug 
loading and precipitation yield is that of a tuberculous drug, rifampicin 
[31]. Solid dispersions of rifampicin loaded in an ethyl cellulose matrix 
were obtained exhibiting a drug loading up to 38.5% and a drug pre-
cipitation yield up to 77.2%.
SAS process has been recently coupled with a fluidized bed for 
elaborating innovative drug formulations [32]. Excipient particles 
(microcrystalline cellulose) have been fluidized under pressure and 
coated with amorphous nanoparticles of naringin, used as a poorly water-
soluble model drug. Higher drug release rates have been mea-sured for 
the innovative SAS formulations in comparison with the ones obtained 
using conventional fluidized bed coating processes.
In addition to conventional drug molecule processing, anti-solvent 
processes appeared to be efficient for the elaboration of sustained re-lease 
drug delivery systems of biomolecules like proteins [33] or of  larger 
biomolecules like nucleic acids [7–9,34]. These works have shown that 
processes using SCFs are suitable for the formulation of nucleic acid 
molecules that are rather fragile. It has been shown by
Fig. 8. SEM images of cefuroxime precipitated from
DMSO at 150 bar, 313 K;(a) sub-microparticles at
50mgmL−1; (b) wrinkled microparticles and shells
at 75mgmL−1 [28].
Several drug molecules have been treated by this process [38]. The SAA 
process can lead to the formation of amorphous particles as well as 
crystalline, starting either from organic phases or aqueous phases.
2.3. SCF used as dispersing agent
Supercritical CO2 can be used as a dispersing agent when it presents 
a certain solubility in the compounds to be precipitated. CO2 solubilizes 
itself in the solutes and/or in the excipients brought to certain condi-
tions of pressure and temperature so as to be molten. This type of 
process is particularly suitable for polymers in which CO2 is sorbed in 
significant quantities, resulting in their plasticization. In that case, 
unlike the other processes described above, the CO2 fraction (relative to 
the global composition) is much lower than in RESS or SAS-type pro-
cesses. This first step of CO2 solubilization is carried out in a high-
pressure vessel often called mixing vessel where the active solute(s) and 
the excipient(s) have been initially placed (see Fig. 10). An adapted 
stirring device has to be used to ensure optimized mixing conditions. An 
anchor type or helicoidal agitation mobiles can be used since the molten 
mixtures are generally viscous. The molten mixture is expanded in a 
second vessel, often called collection or precipitation chamber, placed in 
lower pressure conditions. This expansion can either be car-ried out at 
ambient pressure or at a pressure higher than CO2 critical pressure [39]. 
The expansion is often assisted by a nitrogen or an air flow (or both) so 
as to help the CO2 release and the dispersion of the
formed particles, limiting their coalescence or aggregation, as well as 
their retention on the vessel walls. Nitrogen or air are fed using in-
dividual feed lines or multichannel nozzles, also used for the expansion 
of the molten mixture. As for RESS process, the temperature of the 
mixing vessel, of the collection chamber and of the pre-expansion 
tubing have to be well-chosen and controlled.
In comparison with RESS and SAS-type processes, PGSS process has 
the main advantages of requiring a much smaller quantity of SCF (from 
about 1 to a few g of CO2 per g of solute) and of leading to high pre-
cipitation yieds (frequently 100%). And contrary to the SAS process, the 
use of organic solvents is avoided. Despite these multiple benefits, as for 
RESS-type processes, some issues of tube clogging occuring during the 
expansion or difficulties for properly recovering the particles formed in 
an expansion stream are frequently reported. In addition, precipitation 
occurs during a depressurization phase, thus in transitory conditions. 
This make it more difficult to predict the end-product characteristics and 
to rationalize experimental results.
Nevertheless, the PGSS process is efficient for encapsulating bio-
molecules without any previous step of solubilization of the biomole-
cules either in an organic solvent or in SC CO2. The plasticized polymer 
and a dry powder of the drug solute are mixed under pressure. The dry 
powder of the solute to be trapped can be ground in a preliminary step. 
Ribonuclease A, lysozyme and insulin were coprecipitated in poly(DL-
lactic acid) starting from suspensions of the proteins in the plasticized 
polymer excipient at 32 MPa and 308 K [39]. The mixtures were further
Fig. 9. (a) Raaw quercetin. (b) Pure quercetin crystals formed by SAS process at 10MPa and 308 K; Particle size range: 500–700 nm. (c) Solid dispersions of amorphous quercetin trapped
in ethyl cellulose, formed by SAS process at 10MPa and 308 K; Particle size range: 150–350 nm [30].
Fig. 10. PGSS process flow diagram.
3. Challenges
As seen above, SCF processes applied to drug formulation have been
studied in a rather sustained manner for about thirty years. It is worth
noting that SCF technology for drug formulation emerged in the
industry twenty years ago but has been very slow to be implemented. 
The scale-up is still a real challenge to be overcome for a rather large 
number of cases but much progress has been achieved in recent years.
3.1. Particle collection
As already mentioned above and regardless of the process used, the 
recovery of the nano- or microparticles is not always easy to manage. 
The conditions of particle collection have to meet the Good 
Manufacturing Practices (GMP) guidelines and ensure good efficiency. A 
filtration bag can be used to collect particles in the precipitation 
chamber. For RESS-type and PGSS-type processes, the particles are 
collected from a fluid current. Several methods may be used: particle 
collection by inertial effect (cyclones, impact chambers,…), by elec-
trostatic effect, by washing with liquids or by filtration through a porous 
medium, the last two methods being appropriate for the col-lection of 
ultrafine particles. The particles can also be trapped in a solid powder, 
for example dry ice, or as previously mentioned in a bed of excipient 
[17].
Lastly, to turn a batch process into a semi-batch process, at least two 
collection cells can be used and fed alternatively by the current of fluid 
charged with particles. For the SAS-type process, an additional collec-
tion cell can be used for recovering the powder, turning the semi-con-
tinuous process into a continuous one.
3.2. Residual solvent content
Anti-solvent processes imply the use of an organic solvent that may 
remain present as residual traces in the end-product. It has been seen in 
Section 2.1.2 that the washing step with pure CO2, subsequently to the 
precipitation step is performed not only to renew the fluid content of the 
autoclave and avoid the solvent condensation during depressur-ization 
but also to completely eliminate solvent traces. It is worth noting that 
the powder is required to be evenly distributed in the pre-cipitation cell 
so as to avoid CO2 flowing in preferential paths, thus resulting in a less 
efficient washing and in the formation of particle aggregates. This may 
happen at larger scale. One solution is to alternate washing with a SCF 
flow through the top and bottom of the cell con-taining the powder.
3.3. SCF consumption, purification and recycling
It has been seen that depending on the process considered, the SCF/
solute ratio is different and varies from about 1 to up to 10 000 kg kg−1 
of solute (at lab-scale). This SCF/solute ratio can be reduced during the 
change of scale and a maximum value of 50 kg kg−1 of solute is pre-
ferentially targeted at industrial scale. This ratio has an impact on the 
implementation of the recycling and on the choice of the equipment 
which is dependent on the required fluid flows.
Thus, the fluid recycling implementation will depend on the process 
considered. When the SCF/solute ratio is low (≈1), which could be the 
case for PGSS-type processes, the SCF cannot be recycled. For higher 
ratios, especially for SAS-type and RESS-type processes, the fluid must 
be recycled. Recycling is also necessary when the SCF used is a fluid with 
toxic and/or security problems such as dimethyl ether or propane. Two 
criteria are considered for the SCF recycling: the quantity of the fluid to 
be recycled and the fluid recompression. Up to 98% of the SCF can be 
recycled.
Regarding the purification of the SCF during the recycling, a step of 
separation of the SCF and the organic solvent or solute has to be con-
sidered, especially when the recycling of the fluid takes place at a 
pressure around 5 MPa. The adsorption of the solvent or the solute on an 
activated carbon bed is efficient in numerous cases.
sprayed through a cone nozzle in a collecting chamber placed at lower 
pressure conditions (9 MPa) and filled with nitrogen. The recovered 
coprecipitates exhibited particle sizes ranging from 10 to 300 μm de-
pending on the operating conditions and solute nature.
Another type of drug, the human Growth Hormone-hGH, has also 
been succesfully coprecipitated by Jordan et al. [40] using the PGSS 
process in similar conditions to those mentioned above. Formulations of 
hGH (10 wt%) in PLGA/PLA (80 wt%) and in presence of other ex-
cipients (10 wt%) were elaborated with a drug encapsulation efficiency 
of 100%. The authors performed in vivo studies in rats and cynomolgus 
monkeys demonstrating that the obtained formulations allowed pro-
mising results to be obtained in terms of drug release kinetics, tolerance 
and inflammatory responses. It is worth noting that the stability of hGH 
in SC CO2 was further studied [41], the conclusion being that the hGH 
structural integrity is unaffected by SC CO2 processing under the co-
precipitation conditions of the PGSS-type process used.
Bovine Serum Albumin (BSA) has also been successfully coprecipi-
tated by PGSS process [42]. Formulations of BSA (10 wt%) in triblock 
copolymers (P(L)LA-PEG1.5 kDa-P(L)LA) used as excipients were ela-
borated. It was shown that the triblock molecular weight and the PEG/
PLA ratio influence both the particle size of the coprecipitates and the 
yield while no modification of the shape and of the protein en-
capsulation efficiency was observed.
The use of other types of excipients have also been reported in the 
literature for PGSS process applications. Ribonuclease A was copreci-
pitated by the PGSS process using lipidic compounds (tristearin and 
phosphatidylcholine) as excipients in addition to PEG [43]. The protein 
encapsulation was performed on both the native form and the PEGy-
lated form. It was demonstrated that the PEGylation allows a protein 
integrity protection.
Lipidic compounds have also been used as sole excipients, without 
polymers, for encapsulating Curcumin using the PGSS process [44]. 
Micron-sized coprecipitates of curcumin in a matrix composed of tris-
tearin and soy phosphatidylcholine were elaborated with a drug loading 
varying from 30 to 87 wt%. It should be noted that in that case, it was 
not a solvent-free process since the curcurmin was initially in solution in 
DMSO. As for previous works reported in literature, flows of nitrogen 
and air have been used to assist the spraying of the mixture in the 
collection chamber and to optimize thier collection.
An innovative modified PGSS process was used by Couto et al. [45] 
to elaborate solid lipidic particle encapsulates of a bioactive compound, 
Vitamin B2. The molten mixture composed of fully hydrogenated ca-
nola oil, vitamin B2 and a surfactant (sodium lauryl sulfate) was ex-
panded in a water stream containing PEG used as stabilizer. Aqueous 
suspensions of lipidic nanoparticles encapsulating Vitamin B2 were 
obtained. The authors have discussed the influence of the variation of 
pressure (from 10 to 25 MPa), active solute and surfactant concentra-
tions and of stabilizer MW upon the encapsulation efficiency, bioactive 
load and particle size. For example, the encapsulation efficiency varied 
from 12 up to 48% and the bioactive loads from 0.09 up to 0.73 mg g−1. 
It is worth noting that a lower pressure led to the formation of larger 
particles with higher encapsulation efficiency and active loading. Be-
sides, higher active solute concentrations resulted in larger particles and 
higher encapsulation efficiency as well as active loads.
In addition, it is worth noting that completely different natures of 
compounds, such as virus [46] and bacteria [47], have been copreci-
pitated by the PGSS process.
Lastly, it should be pointed out that the plasticization of polymers 
using SC CO2 is also exploited in another type of process involving 
extruders [48].
4. Knowledge Gaps/Needs
Whatever the process consid a better control of product character-
istics implies more knowledge in terms of thermodynamics and hy-
drodynamics.
Concerning thermodynamics aspects, a first requirement is to 
evaluate the nature of the phases in presence for a given system de-
pending on the conditions of pressure and temperature. The transfer 
kinetics will depend on this. A large number of high-pressure fluid phase 
equilibria for binary systems involving carbon dioxide and or-ganic 
solvents, as well as ternary systems involving CO2, an organic and a 
solute are now available in literature [21,49]. Nevertheless, there is not 
enough data as not all the pressure and temperature ranges usually used 
for particle generation are covered. There is a real need of ex-perimental 
data measurements of high pressure fluid phase equilibria involving 
solutes.
A wide number of works of modeling of high-pressure fluid phase 
equilibria are reported in literature. For the vast majority of them, the 
models used are not predictive and thus require experimental data. A 
step forward would be made if reliable models were developed for the 
prediction of high-pressure fluid phase equilibria involving carbon di-
oxide, organic solvent and solutes of interest for pharmaceuticals. The 
knowledge of these phase equilibria will allow the further study of 
transfer kinetics but it is also helpful for the estimation of solute solu-
bilities [50]. The knowledge of solubilities enables the right operating 
conditions to be chosen in terms of pressure, temperature and global 
composition during the implementation of the processes. This knowl-
edge also allows the further estimation of the supersaturations involved 
during the precipitation phase.
When the crystallization is conducted with the purpose of control-
ling the crystal polymorphic form, this would be easier if the solute 
polymorph phase diagram were known not only at ambient pressure but 
also for high pressure. When a solute presents different poly-morphic 
forms, for the ones presenting enantiomeric systems, the most stable 
form at ambient pressure may not be the most stable at high pressure 
[1]. Thus, a full understanding of the phenomena involved during 
crystallization using SCF may imply a complete knowledge of phase 
equilibria.
Since a large number of polymeric excipients are used, more studies 
on the modification of polymer properties in presence of dense CO2 are 
required. The characterization of the polymer plasticization helps the 
choice of the right operating conditions for a given process. Data such as 
CO2 uptake, glass transition temperature depression, polymer swel-ling 
and so on are of great interest for a good control of polymer pro-cessing. 
Several works have already been reported on these topics [51–55] but 
more data on all the different systems used for drug for-mulation are 
needed.
There is also a knowledge gap concerning the phenomena of nu-
cleation and growth in supercritical media. No fundamental studies have 
been dedicated to the influence of the specific properties of SCF on the 
nucleation frequencies and growth kinetics, considering the usual 
operating conditions of drug particle generation.
Lastly, it has to be highlighted that several works of in situ mea-
surements have been reported over the last decade contributing to filling 
the gaps [56–58]. Indeed, different methods such as in situ FTIR 
measurements or in situ laser scattering allow a deeper study of polymer 
swelling or CO2 uptake, and in a more general way a study of the dif-
ferent interactions between the drug solutes, polymers and SC CO2. 
These techniques will then enable useful information to be provided 
about transfer phenomena involved in the processes of particle gen-
eration using SCF.
5. Future Directions/Perspectives
Now that these different drug particle generation processes have
been mastered, it is of interest to explore a coupling with conventional
methods or with other processes using SCF. For example, supercritical 
extraction of a compound of interest from a dry natural product can be 
easily coupled with a particle generation process that could be im-
plemented subsequently to extraction, in a separation vessel. Integrated 
process can thus be implemented, avoiding or limiting the use of or-
ganic solvent and allowing a good control of the end-product char-
acteristics.
Another application of SC CO2 currently studied, either at lab-scale 
or for industrial applications, is SC CO2 sterilization. Indeed, depending 
on operating conditions, SC CO2 allows complete inactivation or at least 
significant bioburden reduction [59]. It is thus worth noting here, that 
the conditions used for particle generation may correspond to condi-
tions ensuring a significant bioburden reduction, with an efficiency that 
will depend (in addition to the operating conditions) on the initial 
bioburden and the type of contamination. It is then of great interest to 
exploit this specific property of SC CO2.
Furthermore, as a general rule, the current trend in the industry is to 
focus on optimization and intensification aspects. In the particular case 
of supercritical technology, this approach can provide a solution for 
reducing energy consumption. Other advantages like the reduction of 
the unit’s size and thus of the space occupied by the facilities, the de-
crease of the production costs and in addition a higher security of the 
plants are also strengths of these methods. The development in recent 
years of supercritical microfluidic equipment applied to different SCF 
applications will allow progress in this path [60]. The currently pro-
gressing modeling approaches applied to these specific media [61,62] 
will allow a better control of the processes in general and of the in-
tensification in particular. All the different phenomena that have to be 
further studied for a better control of the different processes will then 
also have to be tackled at this lower scale.
As concerns the development of the SCF technology in the phar-
maceutical industry, it is still in the early stages. Although particle 
generation processes using SCFs have been widely studied over the last 
three decades, there are only a few industrial units. Several reasons can 
be given to explain this. First of all, the processes described have not all 
been mature for a long time. Several scale-up issues have been the 
consequences of an improper choice of operating conditions at in-
dustrial scale. For example, as previously mentioned, the duration of the 
precipitation step for anti-solvent processes is of great importance. End-
products with different characteristics are obtained if the pre-cipitation 
step durations are not the same at lab-scale and at industrial scale. The 
different particle design processes using SCFs are now much more 
mature and useful results are now available for more reliable scale-ups. 
Furthermore, some economic data are now available in the literature 
[63]. A second reason may be that the products elaborated using these 
processes did not all fit a market. Indeed, the market for products 
elaborated using environmentally friendly processes is rather recent. 
Moreover, the majority of current legislation all over the world still 
allows the use of conventional liquid organic solvents.
Lastly, an important change in recent years is that several compa-
nies used as service providers can now ensure the scale-up study, the 
production of clinical batches (required for clinical studies) and even 
the production of commercial batches. This allows a product develop-
ment without necessarily requiring investment costs. For all these 
reasons and because SCF technology can be considered as en-
vironmentally friendly, it seems inevitable that its development will 
grow in the pharmaceutical industry in the near future.
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